Roche

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.

LumiraDx - Point of Care Diagnostics Platform Business is an operator of a technology platform.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, the company focuses on discovering and developing therapies for metabolic diseases, including obesity and diabetes. Carmot employs a proprietary drug discovery approach known as Chemotype Evolution, which enables the exploration of novel chemical and biological frontiers. The company is advancing a portfolio of clinical-stage drug candidates, including CT-388, a once-weekly injectable dual GLP-1/GIP receptor agonist; CT-996, a once-daily oral GLP-1 receptor agonist; and CT-868, a once-daily injectable dual GLP-1/GIP receptor agonist for treating type 1 diabetes in patients with overweight or obesity. These innovative therapies aim to enhance glucose clearance and promote weight loss, addressing the fundamental causes of metabolic diseases.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Telavant is developing novel medicines to assist patients suffering from inflammatory and fibrotic disorders.

DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.

Bonum Therapeutics is a biopharmaceutical company focused on developing innovative protein-based drugs designed to treat various diseases, with a primary emphasis on cancer. The company has established a technology platform that enables the creation of drugs with regulated, context-dependent activity. These drugs are engineered to sense their local environment and transition from an inactive to an active form, allowing for targeted therapeutic effects. In addition to cancer, Bonum Therapeutics also aims to address metabolic diseases, immunological conditions, and pain management, thereby expanding its potential impact across multiple therapeutic areas.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

TIB MOLBIOL has been providing custom synthesis of oligonucleotides to a growing number of customers worldwide. Our products are used in the fields of life science research, medical diagnostics, product quality assessment and environmental analysis. Being one of the first suppliers of synthetic DNA in Europe, we have not only set standards of quality and service, but continue to lead in fulfilling your demanding requirements for high quality products and services. The potential of Real-Time PCR was recognized by TIB Molbiol immediately upon its introduction in 1997. The company focused on this new technology by researching new application approaches and experimenting with different technical formats. In 1998 Boehringer Mannheim (now Roche) introduced the LightCycler® Real-Time PCR Instrument. Based on the novel detection format of HybProbes and an innovative thermal cycling technology, the instrument revolutionized Real-Time PCR not only by speeding up the process but also by the versatility of possible experimental applications. TIB Molbiol embraced the new chemistry of HybProbes and embarked with Boehringer Mannheim in a mutual effort to increase the application scope and attractiveness of the instrument.

We're a digital healthcare company on a mission to enhance patients outcome by helping doctors and companies make better decisions through the generation of reliable synthetic data and by developing decision support systems

Soteria Biotherapeutics, Inc., founded in 2018 and based in San Francisco, California, focuses on developing innovative immunotherapies for cancer treatment. The company is creating a new generation of conditionally active bispecific T-cell engaging antibodies specifically aimed at treating solid tumors. Utilizing its advanced T-LITE™ platform, Soteria enables small molecule-dependent activation of these bispecific antibody therapies, which facilitates safer and more effective treatment options. This approach allows for pulsatile activity, resulting in reduced side effects and the potential for higher dosing, thereby improving the overall therapeutic experience for patients.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.

Entrada Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on treating diseases through the intracellular delivery of biologics. Founded in 2016, the company has developed innovative technologies that facilitate the efficient delivery of proteins, peptides, and nucleic acids, targeting intracellular sites that have traditionally been difficult to access. Entrada's approach includes Intracellular Enzyme Replacement Therapy (IC-ERT) and Endosomal Escape Vehicle (EEV) therapeutics, which aim to improve the therapeutic index by enabling the delivery of a wide range of therapeutics across various organs and tissues. The company's pipeline addresses conditions related to neuromuscular diseases and expands into additional therapeutic areas, positioning Entrada at the forefront of advancing treatment options for patients with devastating illnesses.

GenMark Diagnostics is a molecular diagnostics company specializing in the development and commercialization of innovative testing systems that utilize proprietary eSensor electrochemical detection technology. The company offers the ePlex instrument, which combines automated nucleic acid extraction and amplification, allowing for rapid testing of respiratory pathogens by placing patient samples directly into disposable test cartridges. Additionally, GenMark provides the XT-8 System, which has received FDA clearance and can analyze up to 24 test cartridges simultaneously, producing results within 30 minutes of receiving a sample. This system supports a variety of diagnostic tests, including those for respiratory viruses, cystic fibrosis, and hepatitis C genotyping. GenMark Diagnostics sells its products through direct sales and specialized service organizations in the United States and Europe, and is headquartered in Carlsbad, California. The company is also working on the next-generation AD-8 System, which aims to further streamline the testing process by integrating DNA amplification with its sensor detection technology.

Enthera is an Italian biotech start-up focused on developing innovative therapeutic solutions for diabetes, gastrointestinal complications, and other intestinal disorders linked by shared biological pathways. Established in October 2016 through a partnership between BiovelocITA and scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, Enthera aims to address auto-immune disorders by targeting pathways involved in cell apoptosis across the gut, pancreas, and other organs. This approach seeks to enhance treatment options for challenging conditions such as type 1 diabetes and inflammatory bowel disease, thereby contributing to advancements in the management of intractable autoimmune diseases.

Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing innovative small molecule therapies to enhance patient outcomes. Established in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a unique discovery process that leverages clinically validated biological targets alongside advanced chemistry. This methodology aims to overcome the limitations of current therapies by creating potentially first-in-class treatments that address critical challenges such as tolerability, combinability, resistance, and disease progression, particularly in cases involving brain metastases. Enliven's product pipeline includes ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and act against various HER2 variants.

Palladio Biosciences, Inc. is a biotechnology company focused on developing transformative medicines for orphan diseases of the kidney. Founded in 2015 and based in Horsham, Pennsylvania, the company is in the clinical stage and specializes in therapeutics aimed at renal diseases, particularly polycystic kidney disease (PKD). One of its key developments is Lixivaptan, a selective vasopressin V2 receptor antagonist designed to treat PKD, a life-threatening genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. Palladio Biosciences aims to provide innovative treatment options that can help prevent the progression of kidney diseases.

Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, founded in 2016. It specializes in developing orally available drugs aimed at addressing unmet clinical needs in inflammatory diseases by targeting the inflammasome, a component involved in the inflammatory process. The company’s innovative therapies are designed to block inflammasome signals, effectively tackling various inflammatory-driven conditions. These include orphan diseases, central nervous system disorders such as Alzheimer's and Parkinson's, systemic inflammatory diseases like cardiovascular and pulmonary conditions, and applications in ophthalmology and dermatology. By targeting the root causes of inflammation, Inflazome enables the development of precise treatments for a range of diseases, thereby enhancing therapeutic options for healthcare providers. As of September 2020, Inflazome operates as a subsidiary of Roche Holding AG.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Stratos Genomics, Inc. is a Seattle-based company focused on advancing DNA sequencing technology. Founded in 2007, it specializes in a method known as sequencing by expansion, which employs single-molecule detection for genome sequencing and targeted oncology panels. The technology utilizes nanopore systems to identify unique electrical signals associated with each DNA base, facilitating precise and efficient sequencing. Stratos Genomics aims to establish a new standard in DNA sequencing by providing a low-cost, high-fidelity approach that enhances accessibility for scientists and clinicians. As of May 2020, Stratos Genomics operates as a subsidiary of Roche Holding AG.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Purigen Biosystems, Inc. specializes in the manufacture of an ionic purification system aimed at the extraction and purification of nucleic acids from biological samples. Utilizing isotachophoresis, a technique that employs electric fields for the separation and purification of nucleic acids, the company offers an innovative solution that is agnostic to nucleic acid size or sequence. This technology is particularly effective for challenging sample types, including formalin-fixed, paraffin-embedded (FFPE) tissues and low cell counts. Purigen's automated platform processes various biological samples such as mammalian cells, tissue biopsies, plasma, blood, and buccal swabs, delivering ready-to-use DNA or RNA for applications like qPCR, microarray, and next-generation sequencing (NGS) preparations. Founded in 2012 and based in Pleasanton, California, Purigen operates as a subsidiary of Agilent Technologies, providing researchers with a fast and efficient alternative for nucleic acid purification.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.

MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.

Spark Therapeutics, Inc. is a biotechnology company focused on developing gene therapy products aimed at treating debilitating genetic diseases. Headquartered in Philadelphia, Pennsylvania, the company was founded in 2013 and has established itself as a leader in the field of gene therapy, with a robust pipeline that includes LUXTURNA for retinal dystrophy, as well as several candidates for hemophilia and choroideremia. Spark is also exploring therapies for neurodegenerative diseases and inherited retinal diseases. The company holds a collaboration agreement with Pfizer for the development of hemophilia B treatments and has partnered with Novartis for the commercialization of its lead product outside the United States. Spark Therapeutics leverages a proprietary manufacturing platform and a team with extensive expertise in research, clinical development, and regulatory affairs, building on a legacy of innovation in gene therapy from its origins at The Children’s Hospital of Philadelphia. As of December 2019, Spark operates as a subsidiary of Roche Holding AG.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Entrada Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on treating diseases through the intracellular delivery of biologics. Founded in 2016, the company has developed innovative technologies that facilitate the efficient delivery of proteins, peptides, and nucleic acids, targeting intracellular sites that have traditionally been difficult to access. Entrada's approach includes Intracellular Enzyme Replacement Therapy (IC-ERT) and Endosomal Escape Vehicle (EEV) therapeutics, which aim to improve the therapeutic index by enabling the delivery of a wide range of therapeutics across various organs and tissues. The company's pipeline addresses conditions related to neuromuscular diseases and expands into additional therapeutic areas, positioning Entrada at the forefront of advancing treatment options for patients with devastating illnesses.

Tusk Therapeutics Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in developing therapeutic antibodies for cancer treatment. Founded in 2014, the company focuses on immuno-oncology drugs designed to deplete regulatory T-cells (Tregs) and inhibit immunosuppressive cells. Its product pipeline includes agents like CD25, which targets Tregs, and CD38, which functions as an immune checkpoint. Tusk Therapeutics aims to leverage the immune system's capabilities to address the tumor microenvironment, enhancing the immune response against cancer. The company is supported by a team of experienced leaders and scientific advisors with significant expertise in antibody discovery and drug development. As of 2018, Tusk Therapeutics operates as a subsidiary of F. Hoffmann-La Roche Ltd.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

BlueLight Therapeutics Inc. is a protein analysis company based in South San Francisco, California, focused on developing products and systems to analyze real-time protein function for research and clinical applications. Utilizing proprietary second-harmonic generation technology, the company detects conformational changes in proteins and other biological molecules. Its flagship product, the Biodesy Delta System, allows researchers to measure functionally and clinically relevant alterations in protein structure. The company's applications span drug discovery, structural biology, and clinical biomarkers. Additionally, BlueLight Therapeutics employs a structure-based platform to discover small molecules targeting difficult-to-drug proteins, aiming to develop novel therapeutic solutions against high-value drug targets. Founded in 2013 and formerly known as Biodesy, Inc., the company rebranded in May 2020 to reflect its commitment to innovative therapeutic development.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Care Innovations specializes in technology-based healthcare management services that facilitate connections between individuals and caregivers. The company focuses on collecting, aggregating, and analyzing data to deliver actionable insights that bridge the gap between healthcare providers, payers, caregivers, and consumers. By enabling a seamless care continuum within the home, Care Innovations supports individuals in maintaining their independence while also aiming to reduce overall healthcare costs.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

CiVi Biopharma is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular and metabolic diseases, particularly those with significant unmet medical needs. The company is advancing multiple assets in its pipeline, including Intravenous Iloprost, which is currently undergoing Phase 3 trials for the treatment of Systemic Sclerosis. By concentrating on both cardiovascular and rare diseases, CiVi Biopharma aims to provide valuable therapeutic options that enhance patient care and improve health outcomes.

Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Mironid Limited is a drug discovery company based in Newhouse, United Kingdom, focused on developing targeted therapies for degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014, Mironid specializes in creating novel drug candidate molecules by modulating the activity of key cell signaling proteins. Its drug discovery pipeline includes innovative compounds aimed at treating chronic inflammatory diseases and degenerative kidney diseases. The company employs a unique Physiology Mirroring Approach, designing assays that replicate the conformation and environment of drug targets as found in living cells. By focusing on unmet medical needs, Mironid aims to advance its drug development programs, particularly those targeting cAMP-degrading phosphodiesterase enzymes, ultimately striving to deliver effective and differentiated therapies to market.

Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing molecularly targeted therapies aimed at treating cancer and autoimmune diseases. Established in 2011 and based in San Diego, California, Ignyta is dedicated to advancing personalized medicine by integrating therapeutic approaches with companion diagnostics. Its notable products include entrectinib, a tyrosine kinase inhibitor targeting various receptor proteins, and RXDX-105, which is designed for RET-driven solid tumors. The company seeks to improve treatment outcomes by identifying patients most likely to benefit from specific therapies through biomarker-based diagnostics. In 2018, Ignyta became a subsidiary of Roche Holdings, further enhancing its capabilities in precision medicine.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.

Viewics, Inc. specializes in providing Software as a Service (SaaS) business intelligence and analytics solutions tailored for the healthcare sector in the United States and Canada. The company offers the Viewics Data Platform, which connects to various enterprise systems and accepts data in multiple formats for comprehensive analysis. Its flagship product, Viewics Health Insighter, delivers interactive dashboards for clinical, operational, sales, and marketing teams, facilitating informed decision-making. Additionally, Viewics Pulse serves as a web-based platform for data transparency and sharing among clients, patients, payors, and providers. The company’s solutions support clinical laboratories, pathology groups, blood banks, pharmacies, and hospitals, enabling them to gain insights into operational performance, financial management, and compliance. Established in 2010 and based in Sunnyvale, California, Viewics operates as a subsidiary of Roche Holding AG, focusing on empowering healthcare organizations with actionable data insights while alleviating the challenges faced by IT departments.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

mySugr GmbH is a digital health company focused on diabetes management, operating primarily in the United States and European Union. Founded in 2012 and based in Vienna, Austria, mySugr develops comprehensive solutions to assist individuals with diabetes. The mySugr App serves as a central tool that automatically logs blood sugar levels, carbohydrate intake, insulin doses, and activity data, integrating seamlessly with various connected medical devices. Additionally, the company offers features such as the mySugr Scanner for transferring glucose readings directly into the app, mySugr Academy for educational resources on type 2 diabetes, and mySugr Analysis for identifying trends in health data. With a commitment to empowering users through self-management, mySugr also provides unlimited test strips and coaching services, enhancing the overall support for diabetes management. The company operates as a subsidiary of Roche Holding AG since June 2017.

Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

ForSight Labs is dedicated to developing innovative ophthalmic technologies aimed at enhancing the sight and quality of life for visually impaired patients. The organization collaborates with entrepreneurs, investors, and clinicians to drive advancements in eye care through the creation and commercialization of high-impact solutions. With millions of individuals in the U.S. suffering from vision impairment and the associated economic burden exceeding $50 billion annually, ForSight Labs addresses a significant public health challenge. Their focus includes developing treatments for conditions such as glaucoma, which can lead to irreversible blindness in adults. By fostering a creative and cooperative environment, ForSight Labs strives to deliver effective solutions to the ophthalmic community and the patients it serves.

ForSight Labs is dedicated to developing innovative ophthalmic technologies aimed at enhancing the sight and quality of life for visually impaired patients. The organization collaborates with entrepreneurs, investors, and clinicians to drive advancements in eye care through the creation and commercialization of high-impact solutions. With millions of individuals in the U.S. suffering from vision impairment and the associated economic burden exceeding $50 billion annually, ForSight Labs addresses a significant public health challenge. Their focus includes developing treatments for conditions such as glaucoma, which can lead to irreversible blindness in adults. By fostering a creative and cooperative environment, ForSight Labs strives to deliver effective solutions to the ophthalmic community and the patients it serves.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.

Viewics, Inc. specializes in providing Software as a Service (SaaS) business intelligence and analytics solutions tailored for the healthcare sector in the United States and Canada. The company offers the Viewics Data Platform, which connects to various enterprise systems and accepts data in multiple formats for comprehensive analysis. Its flagship product, Viewics Health Insighter, delivers interactive dashboards for clinical, operational, sales, and marketing teams, facilitating informed decision-making. Additionally, Viewics Pulse serves as a web-based platform for data transparency and sharing among clients, patients, payors, and providers. The company’s solutions support clinical laboratories, pathology groups, blood banks, pharmacies, and hospitals, enabling them to gain insights into operational performance, financial management, and compliance. Established in 2010 and based in Sunnyvale, California, Viewics operates as a subsidiary of Roche Holding AG, focusing on empowering healthcare organizations with actionable data insights while alleviating the challenges faced by IT departments.

Fabric Genomics is making genomics-driven precision medicine a reality. We provide clinical decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics.

Purigen Biosystems, Inc. specializes in the manufacture of an ionic purification system aimed at the extraction and purification of nucleic acids from biological samples. Utilizing isotachophoresis, a technique that employs electric fields for the separation and purification of nucleic acids, the company offers an innovative solution that is agnostic to nucleic acid size or sequence. This technology is particularly effective for challenging sample types, including formalin-fixed, paraffin-embedded (FFPE) tissues and low cell counts. Purigen's automated platform processes various biological samples such as mammalian cells, tissue biopsies, plasma, blood, and buccal swabs, delivering ready-to-use DNA or RNA for applications like qPCR, microarray, and next-generation sequencing (NGS) preparations. Founded in 2012 and based in Pleasanton, California, Purigen operates as a subsidiary of Agilent Technologies, providing researchers with a fast and efficient alternative for nucleic acid purification.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. The company's lead product, LUM-201, is an oral small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. In addition to its primary focus, Lumos has a licensing agreement with Ellipses Pharma Limited for the development and commercialization of nanoparticle formulations aimed at oncology indications. Founded in 2011, Lumos Pharma also has a commitment to addressing Creatine Transporter Deficiency, leveraging exclusive licenses for technologies developed at the University of Cincinnati and collaborating with key opinion leaders and the National Institutes of Health. The company engages in both clinical and preclinical research, exploring treatments that may enhance immune responses against cancer, and has partnerships for manufacturing its therapeutics.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

BlueLight Therapeutics Inc. is a protein analysis company based in South San Francisco, California, focused on developing products and systems to analyze real-time protein function for research and clinical applications. Utilizing proprietary second-harmonic generation technology, the company detects conformational changes in proteins and other biological molecules. Its flagship product, the Biodesy Delta System, allows researchers to measure functionally and clinically relevant alterations in protein structure. The company's applications span drug discovery, structural biology, and clinical biomarkers. Additionally, BlueLight Therapeutics employs a structure-based platform to discover small molecules targeting difficult-to-drug proteins, aiming to develop novel therapeutic solutions against high-value drug targets. Founded in 2013 and formerly known as Biodesy, Inc., the company rebranded in May 2020 to reflect its commitment to innovative therapeutic development.

Tensha Therapeutics specializes in the development of small molecule bromodomain inhibitors, which are a novel class of epigenetic modulators designed to influence gene expression for the treatment of cancer and other serious disorders. Founded on research from Dr. James Bradner at the Dana-Farber Cancer Institute, the company is advancing first-in-class, potent BET bromodomain inhibitors. Its lead program targets conditions such as BRD4-NUT midline carcinoma, acute myeloid leukemia, and multiple myeloma, among others. Tensha Therapeutics operates as a focused company backed by HealthCare Ventures, aiming to address significant unmet medical needs in oncology.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates that target and eliminate disease-causing proteins, primarily for the treatment of cancer and neurodegenerative disorders. The company's lead product candidate, CFT7455, is an orally bioavailable degrader designed to target IKZF1/3 for multiple myeloma and other lymphomas. Additionally, C4 is advancing CFT8634, which targets BRD9 for specific solid tumors, alongside programs aimed at genetically defined resistant solid tumors. C4 Therapeutics utilizes its proprietary Degronimid platform, which allows for the selective degradation of proteins through the natural ubiquitin/proteasome system, potentially addressing previously undruggable targets while minimizing drug resistance. The company has formed strategic collaborations with major industry players, and it aims to make a significant impact on the treatment landscape through its advanced protein degradation science and multiple development programs. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics continues to innovate in the field of targeted therapy.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Kapa Biosystems, Inc. specializes in the development and supply of life science reagents for DNA and RNA amplification, sequencing, and molecular diagnostics. The company offers a range of products, including next-generation sequencing platforms for various applications such as whole genome and RNA sequencing, as well as qPCR products for gene expression and genotyping. Kapa's proprietary protein engineering technologies enhance the performance of enzymes used in these processes, aiming to reduce costs, simplify workflows, and improve outcomes in biomedical research. Founded in 2006 and based in Wilmington, Massachusetts, Kapa also maintains a research and manufacturing facility in Cape Town, South Africa. The company operates as a subsidiary of Roche Holding AG.

MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Adheron Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for rheumatoid arthritis and fibrotic diseases, including pulmonary and skin fibrosis. The company’s lead product, SDP051, is a Cadherin-11 antagonist designed to disrupt cell adhesion, which can influence the production of various proteins within the cellular environment. This therapeutic approach aims to provide a next-generation, non-immunosuppressive treatment for fibrosis and to address the debilitating effects of cartilage destruction associated with rheumatoid arthritis. Established in 2006 as Synovex Corporation and based in Berkeley, California, Adheron Therapeutics is built upon pioneering research conducted by Dr. Michael Brenner at Brigham and Women's Hospital and Harvard Medical School. As of October 2015, Adheron operates as a subsidiary of Roche Holding AG.

AveXis, now known as Novartis Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies aimed at treating rare and life-threatening neurological genetic disorders. Acquired by Novartis in 2018, the company specializes in motor neuron cell-targeted gene replacement therapies for conditions such as spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. By addressing these severe diseases, which often result in progressive muscle weakness, paralysis, and death, AveXis plays a crucial role in enhancing treatment options for affected patients and their families.

GeneWeave Biosciences specializes in developing advanced diagnostic solutions to enhance clinical microbiology and address the challenges posed by drug-resistant infections. The company aims to support hospitals and physicians globally by enabling improved antibiotic stewardship and providing rapid determinations of optimal antibiotic therapy for critical bacterial infections. Utilizing its proprietary Smarticles™ technology, GeneWeave delivers homogeneous assays that can quickly measure bacterial drug resistance without the need for enrichment, culture, or extensive sample preparation, thereby streamlining the diagnostic process and contributing to better patient outcomes.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Stratos Genomics, Inc. is a Seattle-based company focused on advancing DNA sequencing technology. Founded in 2007, it specializes in a method known as sequencing by expansion, which employs single-molecule detection for genome sequencing and targeted oncology panels. The technology utilizes nanopore systems to identify unique electrical signals associated with each DNA base, facilitating precise and efficient sequencing. Stratos Genomics aims to establish a new standard in DNA sequencing by providing a low-cost, high-fidelity approach that enhances accessibility for scientists and clinicians. As of May 2020, Stratos Genomics operates as a subsidiary of Roche Holding AG.

mySugr GmbH is a digital health company focused on diabetes management, operating primarily in the United States and European Union. Founded in 2012 and based in Vienna, Austria, mySugr develops comprehensive solutions to assist individuals with diabetes. The mySugr App serves as a central tool that automatically logs blood sugar levels, carbohydrate intake, insulin doses, and activity data, integrating seamlessly with various connected medical devices. Additionally, the company offers features such as the mySugr Scanner for transferring glucose readings directly into the app, mySugr Academy for educational resources on type 2 diabetes, and mySugr Analysis for identifying trends in health data. With a commitment to empowering users through self-management, mySugr also provides unlimited test strips and coaching services, enhancing the overall support for diabetes management. The company operates as a subsidiary of Roche Holding AG since June 2017.

Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.

Signature Diagnostics GmbH is a translational oncology and genomics company based in Potsdam, Germany, founded in 2004. The company specializes in the development of extensive biobanks comprising blood plasma and tumor tissue samples from cancer patients, particularly focusing on colorectal and lung cancers through multicenter prospective clinical studies. Signature Diagnostics also creates next-generation sequencing assays utilizing targeted gene panels and demonstrates expertise in ultra-deep sequencing tests that leverage circulating free DNA (cfDNA). These advancements aim to enhance non-invasive monitoring of treatment responses in cancer patients. Additionally, Signature has developed molecular oncology diagnostic products for early cancer detection and prognosis, which have been launched from its ISO 15189 certified service laboratory. The company collaborates with various clinical, pharmaceutical, and diagnostic partners to further its research and product development initiatives. As of February 2015, it operates as a subsidiary of Roche Holding AG.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Founded in 2011 and based in Cambridge, Massachusetts, the company targets disorders such as Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. Lysosomal Therapeutics employs a unique molecular platform informed by the clinically validated connection between lysosomal disorders and neurodegeneration. This approach facilitates the development of innovative treatment options aimed at improving the health and quality of life for patients affected by these debilitating conditions.

Trophos is a clinical stage pharmaceutical company focused on developing innovative therapeutics for underserved needs in neurology and cardiology. The company has a fully integrated approach, with a pipeline of original molecules targeting conditions such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), chemotherapy-induced peripheral neuropathy, and cardiac ischemia-reperfusion injury. Trophos employs a method of screening small chemical molecules on models of the specific neurons affected by these diseases, aiming to create effective treatments for challenging medical conditions.

Foundation Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in providing molecular information products for cancer diagnosis and treatment. The company utilizes advanced genomic profiling technologies to analyze tumor specimens, enabling healthcare providers to gain insights into individual patients' cancer profiles. This information assists in optimizing treatment strategies, particularly for targeted therapies and immunotherapies. Foundation Medicine’s product offerings include FoundationOne for solid tumors, FoundationOne Heme for blood-based cancers, and various diagnostic assays to support clinical decision-making in oncology. The company also maintains a knowledgebase, FoundationCORE, to disseminate scientific advancements and strengthen collaborations within the oncology community. Foundation Medicine has established strategic partnerships with major pharmaceutical companies and research organizations to enhance precision medicine initiatives and develop companion diagnostics for specific therapies. Founded in 2009, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc.

AveXis, now known as Novartis Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies aimed at treating rare and life-threatening neurological genetic disorders. Acquired by Novartis in 2018, the company specializes in motor neuron cell-targeted gene replacement therapies for conditions such as spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. By addressing these severe diseases, which often result in progressive muscle weakness, paralysis, and death, AveXis plays a crucial role in enhancing treatment options for affected patients and their families.

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company based in South San Francisco, California. It specializes in developing a novel class of antibody therapeutics utilizing its Probody technology platform, which aims to enhance the targeting of tumors while minimizing drug activity in healthy tissues. The company's clinical-stage product candidates include CX-072, a therapeutic targeting programmed cell death ligand 1; CX-2009, a drug conjugate targeting CD166; BMS-986249 and BMS-986288, both targeting CTLA-4 for metastatic melanoma and solid tumors; and CX-2029, a drug conjugate for CD71 in solid tumors. CytomX collaborates strategically with several industry leaders, including AbbVie, Amgen, and Bristol-Myers Squibb, to advance its Probody therapeutics. Founded in 2008, CytomX Therapeutics is committed to providing innovative and less toxic treatment options for patients with severe illnesses such as cancer.